ResMed stock overview after recent performance shift
ResMed (RMD) has drawn fresh attention after recent share price weakness, with the stock showing a 14.1% decline over the past month and a 9.5% decline over the past 3 months, prompting closer scrutiny of its fundamentals.
See our latest analysis for ResMed.
Zooming out, the recent 1 month share price return of 14.1% decline and 3 month share price return of 9.5% decline sit against a 1 year total shareholder return of 0.8% decline and a 5 year total shareholder return of 17.7%. This suggests short term momentum has faded while longer term holders have still seen positive overall outcomes.
If you are rethinking your healthcare exposure after ResMed's recent moves, it could be a good time to scan other potential opportunities in specialist care technology through 34 healthcare AI stocks
With ResMed trading at US$220.03 against an analyst price target of US$296.87 and an estimated intrinsic discount of 21.2%, it is worth asking whether this represents a genuine opportunity or whether the market is already pricing in its growth.
Most Popular Narrative: 25.9% Undervalued
ResMed's most followed narrative sees fair value at $296.87 compared with the last close of $220.03, setting up a valuation story built around earnings visibility and margins.
Acceleration in adoption of home-based, cloud-connected therapy solutions and digital health platforms (including software like Brightree and AirView) enhances recurring high-margin revenue streams and increases both user retention and net profit margins over time.
Read the complete narrative. Read the complete narrative.
Curious what kind of revenue path, margin profile, and earnings multiple are needed to support that price tag? The underlying narrative emphasizes durable profit growth, richer margins and a premium P/E that remains below many peers.
Result: Fair Value of $296.87 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you also need to factor in risks like tighter reimbursement policies or rival therapies, which could pressure pricing power and challenge the margin-focused narrative.
Find out about the key risks to this ResMed narrative.
Next Steps
With sentiment mixed across valuation, growth, and risk, it helps to move quickly, review the underlying data for yourself, and decide what really matters. To see what the market is optimistic about, take a close look at the 5 key rewards
Looking for more investment ideas?
If you stop at just one stock, you could miss stronger opportunities elsewhere, so use this moment to widen your search and pressure test your next move.
- Spot potential turnaround candidates early by checking out 32 elite penny stocks with strong financials that already back their share price with concrete fundamentals.
- Hunt for quality at a sensible price by reviewing 62 high quality undervalued stocks that pair solid cash flows with balance sheets that can support future plans.
- Prioritise resilience in choppy markets by scanning 62 resilient stocks with low risk scores where business strength and risk scores stay front and centre.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com